Kidney Disease & Nephrology Clinical Trials Update: Week 26, 2026

Published June 26, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease

This Phase 4 trial is testing finerenone, an oral medication, for adults in China with type 2 diabetes and chronic kidney disease who have albuminuria, a sign of kidney damage. If finerenone proves effective, it could become a new treatment option to help slow the progression of kidney damage and improve health outcomes for patients already receiving standard care. The study plans to follow 148 participants for six months to see how well finerenone reduces albuminuria.

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

This Phase 3 trial is focusing on adolescents aged 12 to under 18 who have had a kidney transplant. It compares switching their immunosuppressive treatment to belatacept against continuing the current calcineurin inhibitor regimen. The goal is to see if belatacept improves the survival of the transplanted kidney and helps teenagers better stick to their medication schedules. Results are expected after two years of follow-up in multiple countries.

Effect of Low Doses of Hypoxia-inducible Factor- Prolyl Hydroxylase Enzyme Inhibitor Plus Iron in the Treatment of Anemia in Dialysis-dependent Chronic Kidney Disease Patients

This Phase 4 study tested a new pill combining low doses of Roxadustat, a drug that helps the body produce red blood cells, with iron supplements in patients on dialysis who have anemia. Anemia is common in chronic kidney disease and often requires injections, so this oral treatment could offer a more convenient and potentially safer option. The trial, completed in Egypt with 72 patients, may help improve anemia management for those on dialysis.

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

This Phase 3 trial is comparing SNP-ACTH (1-39) Gel to rituximab, a current treatment, for adults with primary membranous nephropathy, an autoimmune kidney disease. Researchers hope the gel can better improve kidney function and reduce harmful antibodies that damage the kidneys. The study is actively recruiting in countries including the United States, Canada, and India, with results anticipated after two years.

Colistin Nephrotoxicity and Role of Alpha Lipoic Acid

This Phase 3 trial is investigating whether alpha lipoic acid can protect the kidneys from damage caused by colistin, an antibiotic known to sometimes harm kidney function. If successful, this could offer a new way to reduce kidney injury in hospitalized adults treated with colistin. The study is recruiting patients in Egypt and uses specific markers to carefully monitor kidney health during treatment.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.